Table 1.
Outcomes for oocytes collected from ovaries
| Patient | Agea | No. viable oocytes collected | IVM to MII for up to 48 h (%)b | No. oocytes survived after warming (%) | No. oocytes activated (%) | No. oocytes further developed (up to 6 days) (%) | Patient diagnosis |
|---|---|---|---|---|---|---|---|
| 1 |
18 |
9 |
2 |
1 |
1 |
0 |
Sex reassignment surgery |
| 2 |
24 |
19 |
14 |
10 |
7 |
4c |
Sex reassignment surgery |
| 3 |
25 |
11 |
9 |
4 |
3 |
0 |
Cystic adnexal mass |
| 4 |
29 |
4 |
2 |
2 |
2 |
2 |
Cystic adnexal mass |
| 5 |
39 |
5 |
2 |
2 |
1 |
1 |
Cystic adnexal mass |
| 6 |
37 |
5 |
5 |
4 |
3 |
0 |
Cervical adenocarcinoma |
| 7 |
41 |
10 |
5 |
1 |
1 |
1 |
Cervical adenocarcinoma |
| Total |
|
63 |
39/63 (61.9%) |
24/39 (61.5%) |
18/24 (75%) |
8/18 (44.4%) |
8/63 (12.7%) |
| P valued | 0.84 | 0.53 | 1.0 | 0.70 |
No statistically significant differences were found between different patient diagnosis (SRS, adnexal mass, and adenocarcinoma) at each step (IVM, oocyte activation and development).
a Age of patient at the time of oocyte collection.
b All MII oocytes were vitrified after IVM.
c One embryo reached the blastocyst stage.
d Fisher’s exact test.
IVM, in vitro maturation; MII, metaphase II.